Advertisement
Advertisement
U.S. Markets close in 6 hrs 29 mins
Advertisement
Advertisement
Advertisement
Advertisement

LivaNova PLC (LIVN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
64.44-2.18 (-3.27%)
As of 04:00PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close66.62
Open65.40
Bid26.05 x 800
Ask0.00 x 1100
Day's Range64.10 - 64.10
52 Week Range58.18 - 93.89
Volume948
Avg. Volume370,204
Market Cap3.43B
Beta (5Y Monthly)0.91
PE Ratio (TTM)N/A
EPS (TTM)-8.23
Earnings DateApr 26, 2022 - May 02, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est100.33
  • American City Business Journals

    ALung acquired by London-based health care company

    ALung Technologies Inc., whose HemoLung product developed out of the University of Pittsburgh helps patients with acute respiratory distress, has been acquired by a London-based medical technology company. LivaNova (NASDAQ: LIVN) acquired ALung for $10 million with additional payments on sales-based milestones in the future, according to LivaNova's first-quarter earnings report that was released Wednesday. "ALung products are complementary to LivaNova's ACS portfolio and, as such, the business and financial results will be included in the company's ACS (Advanced Circulatory Support) segment," LivaNova said.

  • Zacks

    LivaNova (LIVN) Lags Q1 Earnings Estimates

    LivaNova (LIVN) delivered earnings and revenue surprises of -7.69% and 3.09%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wire

    LivaNova Reports First-Quarter 2022 Results

    LONDON, May 04, 2022--LivaNova PLC, a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2022.

Advertisement
Advertisement